Vijaya Diagnostic Centre Limited reported a 36.1% year-on-year increase in consolidated net profit to ₹531.01 lakh for the first quarter ended June 30, 2026, driven by robust growth in revenue from operations. Consolidated revenue rose 22.8% to ₹2,309.82 lakh from ₹1,880.53 lakh in the corresponding period of the previous year, reflecting strong demand in its diagnostic services segment. The Board of Directors, meeting on August 06, 2026, approved the unaudited standalone and consolidated financial results and recommended a dividend of Re. 2 per equity share, representing a 200% payout for the financial year 2025-26, pending approval at the ensuing Annual General Meeting.

The filing was submitted pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors B S R and Co conducted a limited review of the interim financial information and issued an unmodified report. The results were prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. Management highlighted that the comparative figures have been restated to reflect the amalgamation of Medinova Diagnostic Services Limited, approved by the National Company Law Tribunal (NCLT) on October 13, 2025, ensuring consistent presentation across reporting periods.

Financial Performance Highlights

Consolidated profit before tax increased to ₹709.45 lakh from ₹522.07 lakh in Q1FY25, aided by operational efficiencies despite a rise in total expenses to ₹1,685.68 lakh. Standalone net profit also grew significantly, reaching ₹531.48 lakh compared to ₹390.50 lakh in the prior year period. Earnings per equity share (basic) stood at ₹5.16 on a consolidated basis and ₹5.17 on a standalone basis, up from ₹3.76 and ₹3.80 respectively in the same quarter last year.

Operational Updates and Corporate Actions

During the quarter, the company granted 179,500 employee stock options to eligible employees under the 'Employee Stock Option Plan 2018', as approved by the Nomination and Remuneration Committee on May 07, 2026. This move aligns with the company's strategy to retain key talent amidst expansion. Additionally, the Board had previously approved the acquisition of Medinova Millennium MRI Services LLP via a slump sale, accounted for using the pooling of interest method under Ind AS 103. This transaction has been integrated into the financial statements, with assets and liabilities recorded at their existing carrying amounts.

What the Numbers Show

The divergence between revenue growth (22.8%) and expense growth (18.0%) indicates improving operating leverage for Vijaya Diagnostic Centre Limited. While employee benefits and finance costs rose due to business expansion and inflationary pressures, the company managed to control cost of materials consumed relative to revenue. The significant jump in net profit, outpacing revenue growth, suggests that fixed costs are being spread over a larger revenue base, enhancing overall profitability margins. The proposed 200% dividend further signals management's confidence in cash flow generation and commitment to shareholder returns.

Vijaya Diagnostic Centre Limited will participate in the EMKAY Confluence 2026 annual investor conference on August 12, 2026, providing a platform for engagement with financial analysts and institutional investors. The company’s officials are scheduled to hold both group and one-on-one meetings in Mumbai from 9:00 AM to 5:00 PM (IST). This participation aims to facilitate direct dialogue regarding the company’s business outlook, strictly adhering to regulatory guidelines that prohibit the disclosure of any unpublished price-sensitive information.

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Vijaya Diagnostic Centre Limited submitted the intimation to the Listing Department of the National Stock Exchange of India Limited and the Corporate Relations Department of BSE Limited on July 29, 2026. The disclosure ensures transparency and keeps the market informed about upcoming corporate engagements with key stakeholders.

Meeting Schedule Details

The conference is structured to allow for comprehensive interaction between the company’s management and the investment community. The specific details of the engagement are outlined below:

Company Secretary Naga Vasudha Tadepalli signed the disclosure, confirming the schedule. The company noted that the schedule is subject to change due to exigencies on the part of participants or the company itself. Investors and analysts are encouraged to approach the company for any clarifications regarding discussions held during the meeting after the event concludes.

Compliance and Information Scope

Vijaya Diagnostic Centre Limited emphasized that all discussions during the EMKAY Confluence 2026 will be based solely on publicly available information. The company explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during these interactions. This compliance measure aligns with SEBI’s regulations designed to prevent insider trading and ensure fair market practices.

The full text of the intimation is available on the company’s website under the investor relations section. This proactive disclosure supports the company’s commitment to maintaining open lines of communication with its shareholders and the broader financial community while upholding strict regulatory standards.